Spear Bio
Spear Bio is a cutting-edge biotechnology company dedicated to developing innovative therapies for patients with unmet medical needs. Our team of experienced scientists and researchers are focused on discovering and developing novel medicines to treat a wide range of diseases.
Latest Content
App Note / Case Study
An Innovative pTau 217 Assay Unlocks New Possibilities in Alzheimer’s Disease Research
This case study shows how a next-generation pTau 217 assay achieves higher accuracy than existing platforms using only 1 µL of diluted plasma, while maintaining robust performance across freeze-thawed samples and diverse cohorts.
Product News
Spear Bio Secures FDA Breakthrough Device Designation for its Novel pTau 217 Blood Test, Advancing Scalable Solutions for Early Alzheimer's Disease Diagnosis
Spear Bio Inc., announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
Advertisement
